(Q33333849)

25 July 2017

title

A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study (English)

1 reference

heparin-induced thrombocytopenia

25 July 2017

1 reference

1 reference

1 reference

Huhle G

1

1 reference

25 July 2017

Hoffmann U

2

1 reference

25 July 2017

Hoffmann I

3

1 reference

25 July 2017

Liebe V

4

1 reference

25 July 2017

Harenberg JF

5

1 reference

25 July 2017

Heene DL

6

1 reference

25 July 2017

publication date

1 August 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

99

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

325-334

1 reference

Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and FC fragments on antibody-heparin-platelet interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Immune endothelial-cell injury in heparin-associated thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

The complete amino acid sequence of hirudin, a thrombin specific inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

The development of hirudin as an antithrombotic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Recombinant hirudin: genetic engineering and structure analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Hirudins: from leeches to man.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Anticoagulation in patients with heparin-induced thrombocytopenia type II.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Quantitative determination of hirudin in blood and body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Comparative studies on various assays for the laboratory evaluation of r-hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Immunoassays in monitoring biotechnological drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Preparation of monoclonal antibodies to the thrombin/hirudin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

Clinico-pharmacological studies with recombinant hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900253-X

7 January 2021

10.1016/S0049-3848(00)00253-X

Identifiers

DOI

1 reference

25 July 2017

1 reference